Published in Brain on July 01, 2002
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med (2010) 4.78
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 2.96
Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest (2006) 2.75
Development, maintenance and disruption of the blood-brain barrier. Nat Med (2013) 2.62
Aquaporin 4 and neuromyelitis optica. Lancet Neurol (2012) 2.58
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med (2008) 2.15
Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol (2012) 2.06
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain (2007) 1.94
Theiler's virus infection: a model for multiple sclerosis. Clin Microbiol Rev (2004) 1.92
Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol (2009) 1.88
Oligodendrocytes: biology and pathology. Acta Neuropathol (2009) 1.81
Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology (2014) 1.80
Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol (2013) 1.79
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease. Neurology (2013) 1.77
Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol (2012) 1.75
Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol (2011) 1.72
Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord (2012) 1.62
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol (2014) 1.60
Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci (2007) 1.59
A population-based study of neuromyelitis optica in Caucasians. Neurology (2011) 1.58
Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem (2012) 1.55
Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol (2012) 1.54
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol (2014) 1.53
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology (2009) 1.52
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Human aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with neuromyelitis optica. Arch Neurol (2012) 1.47
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Demyelinating diseases. J Clin Pathol (2006) 1.41
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest (2005) 1.41
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol (2010) 1.37
Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation (2008) 1.32
Targeting experimental autoimmune encephalomyelitis lesions to a predetermined axonal tract system allows for refined behavioral testing in an animal model of multiple sclerosis. Am J Pathol (2004) 1.31
Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry (2006) 1.31
Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol (2009) 1.31
The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol (2009) 1.29
Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res (2011) 1.28
Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol (2012) 1.28
Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One (2013) 1.21
An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc Natl Acad Sci U S A (2005) 1.19
Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One (2013) 1.18
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol (2012) 1.17
Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol (2007) 1.17
Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol (2006) 1.16
Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One (2011) 1.13
Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci (2010) 1.13
Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One (2010) 1.13
A possible paraneoplastic neuromyelitis optica associated with lung cancer. Neurol Sci (2009) 1.12
Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest (2013) 1.12
Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol (2010) 1.11
Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int (2012) 1.10
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler (2012) 1.10
Fulminant demyelinating diseases. Neurohospitalist (2013) 1.10
New insights into neuromyelitis optica. J Clin Neurol (2011) 1.09
Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol (2010) 1.08
Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. Glia (2012) 1.08
Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol (2008) 1.07
Absence of cortical demyelination in neuromyelitis optica. Neurology (2010) 1.07
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci (2015) 1.07
Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol (2013) 1.06
Optic neuritis. Eye (Lond) (2011) 1.05
Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol (2013) 1.05
B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol (2014) 1.01
Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. Acta Neuropathol (2015) 1.00
Diagnosis of inflammatory demyelination in biopsy specimens: a practical approach. Acta Neuropathol (2008) 0.99
B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity. Ann Neurol (2015) 0.98
Association of neuromyelitis optica with severe and intractable pain. Arch Neurol (2012) 0.98
Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Mult Scler (2012) 0.97
Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci (2015) 0.96
Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol (2013) 0.96
Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) (2013) 0.96
T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathol Commun (2013) 0.96
Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG. Acta Neuropathol (2013) 0.95
Brain-reactive antibodies and disease. Annu Rev Immunol (2013) 0.94
Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathol (2013) 0.94
Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol (2013) 0.94
Is multiple sclerosis an autoimmune disease? Autoimmune Dis (2012) 0.94
Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol (2010) 0.93
Oligodendrocyte-microglia cross-talk in the central nervous system. Immunology (2014) 0.93
Neuromyelitis Optica. Curr Treat Options Neurol (2005) 0.93
CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. Am J Pathol (2003) 0.93
Recent neuropathological findings in MS--implications for diagnosis and therapy. J Neurol (2004) 0.93
The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. Int J Mol Sci (2016) 0.93
Type I interferons as ambiguous modulators of chronic inflammation in the central nervous system. Front Immunol (2012) 0.92
Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci (2012) 0.92
C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol (2013) 0.92
A mighty mouse: building a better model of multiple sclerosis. J Clin Invest (2006) 0.92
Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions. BMC Neurol (2013) 0.91
Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol (2013) 0.91
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics (2016) 0.91
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 10.99
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron (2012) 5.84
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A (2007) 3.61
Neuromyelitis optica. J Neuroophthalmol (2012) 3.29
Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One (2010) 3.24
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet (2011) 3.16
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 3.06
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med (2010) 2.98
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol (2005) 2.96
Cortical demyelination in PML and MS: Similarities and differences. Neurology (2008) 2.75
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain (2009) 2.74
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol (2004) 2.65
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Development, maintenance and disruption of the blood-brain barrier. Nat Med (2013) 2.62
Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 2.61
The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol (2003) 2.58
Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology (2002) 2.52
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Disease-specific molecular events in cortical multiple sclerosis lesions. Brain (2013) 2.48
Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol (2006) 2.48
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol (2008) 2.46
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron (2008) 2.44
Remyelination is extensive in a subset of multiple sclerosis patients. Brain (2006) 2.43
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum (2007) 2.42
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol (2009) 2.41
Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci (2004) 2.35
Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity (2010) 2.32
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest (2006) 2.32
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A (2003) 2.30
Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood (2008) 2.26
CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol (2010) 2.25
Regulation of tau pathology by the microglial fractalkine receptor. Neuron (2010) 2.24
Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol (2007) 2.18
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol (2002) 2.17
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 2.17
The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med (2007) 2.16
Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol (2009) 2.15
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med (2009) 2.13
Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol (2012) 2.09
Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat Protoc (2006) 2.08
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain (2005) 2.07
A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci U S A (2009) 2.04
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology (2004) 2.04
The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J (2006) 2.04
Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Arch Neurol (2006) 2.02
Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol (2012) 2.01
Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA (2013) 2.00
Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging (2007) 2.00
The role of nitric oxide in multiple sclerosis. Lancet Neurol (2002) 2.00
Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage (2008) 1.98
The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol (2011) 1.96
Oxidative damage in multiple sclerosis lesions. Brain (2011) 1.95
Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain (2007) 1.94
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain (2007) 1.94
Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain (2009) 1.93
Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol (2008) 1.93
Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging (2006) 1.92
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med (2002) 1.91
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
Rates of cerebral atrophy differ in different degenerative pathologies. Brain (2007) 1.90
The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med (2004) 1.90
Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc (2010) 1.85
Natalizumab and PML. Nat Neurosci (2005) 1.85
Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol (2005) 1.85
Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol (2004) 1.83